Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 317 pages

Showing 251 - 300


leukemia
issues in oncology

Protein-Based Therapy Shows Promise Against Resistant ALL in Preclinical Study

Chemotherapy resistance is one of the most formidable obstacles to treating acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Now researchers at Children’s Hospital Los Angeles (CHLA) have designed and developed a new protein-based therapy that may prove highly...

leukemia

CPX-351 Receives Fast Track Designation for Secondary Acute Myeloid Leukemia in Elderly Patients

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Celator Pharmaceuticals’ investigational agent CPX-351, a liposomal formulation of cytarabine-daunorubicin, for the treatment of elderly patients with secondary acute myeloid leukemia. The FDA established the...

leukemia

Long Noncoding RNAs Are a Novel Prognostic Marker in Older Patients With Acute Leukemia

A new study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) describes a novel marker that might help doctors choose the least toxic, most effective treatment for many...

leukemia

ASH 2014: Pracinostat Combination Shows Significant Clinical Activity in Phase II Study of Newly Diagnosed Acute Myeloid Leukemia

In a phase II study, the histone deacetylase inhibitor pracinostat demonstrated significant clinical activity in combination with azacitadine in elderly patients with newly diagnosed acute myeloid leukemia (AML). Interim data from 33 evaluable patients were presented at the 56th American Society of ...

leukemia

ASH 2014: Oral Inhibitor Shows Clinical Activity in Poor-Prognosis AML

An oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML), a poor-prognosis group with few options, reported investigators from Dana-Farber Cancer Institute and The University of Texas MD...

leukemia
survivorship

ASH 2014: Common Genetic Variations May Contribute to Treatment-Related Cognitive Problems in Children With Leukemia

Common variations in four genes related to brain inflammation or cells′ response to damage from oxidation may contribute to the problems with memory, learning, and other cognitive functions seen in children treated for acute lymphoblastic leukemia (ALL), according to a study presented at the...

leukemia
myelodysplastic syndromes

ASH 2014: Combination Therapy Shown to Be Effective for Patients With Myelodysplastic Syndrome and AML

A phase II study investigating the potential of the drugs azacitidine and lenalidomide (Revlimid) demonstrated that the two therapies in combination may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia (AML). The...

leukemia

ASH 2014: Pediatric Leukemia Treatment Regimens Lead to Improved Outcomes in Adolescents, Young Adults

Results from a large prospective study suggest that children and young adults with acute lymphocytic leukemia (ALL) may respond better to a chemotherapy regimen pioneered in pediatric patients. The findings were presented at the 56th American Society of Hematology (ASH) Annual Meeting and...

leukemia

FDA Approves Blinatumomab to Treat Rare Form of Acute Lymphoblastic Leukemia

The U.S. Food and Drug Administration (FDA) today granted accelerated approval to blinatumomab (Blincyto) for the treatment of patients with Philadelphia chromosome–negative, relapsed or refractory precursor B-cell acute lymphoblastic leukemia (B-cell ALL). Blinatumomab is a bispecific...

leukemia

FDA Grants Breakthrough Therapy Designation to Investigational CAR T-Cell Therapy

The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to JCAR015, an investigational chimeric antigen receptor therapy developed by Juno Therapeutics. The designation applies for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia and was filed...

leukemia

IDH1 Inhibitor Demonstrates Anticancer Activity in Advanced Leukemia

A phase I trial of the first drug designed to inhibit the cancer-causing activity of a mutated enzyme known as isocitrate dehydrogenase (IDH) 1, which is involved in cell metabolism, has shown clinical activity in patients with advanced acute myeloid leukemia (AML) with the IDH1 mutation. The...

leukemia

FDA Grants Orphan Drug Designation to BGB324 for Acute Myeloid Leukemia

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BGB324 for the treatment of acute myeloid leukemia (AML). BGB324 is a first-in-class, highly selective small-molecule inhibitor of the Axl receptor tyrosine kinase. It blocks the epithelial-mesenchymal transition...

leukemia

Blinatumomab Receives FDA Priority Review Designation in Acute Lymphoblastic Leukemia

The U.S. Food and Drug Administration (FDA) has accepted for review Amgen’s Biologics License Application for blinatumomab for the treatment of adults with Philadelphia chromosome–negative relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). As part of the acceptance, the ...

leukemia

Genomic Analysis Reveals That a High-Risk Leukemia Subtype Becomes More Common With Age

More than one-quarter of young adults with the most common form of acute lymphoblastic leukemia have a high-risk subtype with a poor prognosis and may benefit from drugs widely used to treat other types of leukemia that are more common in adults, according to multi-institutional research led by St. ...

leukemia

Study Provides Blueprint for Next Generation of Chronic Myeloid Leukemia Treatment

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have identified and characterized mutated forms of the gene that encodes BCR-ABL, the unregulated enzyme driving chronic myeloid leukemia (CML). The findings by Zabriskie et al were published in Cancer Cell. Although tyrosine ...

hematologic malignancies
leukemia
myelodysplastic syndromes

Past Exposure to Thiopurines Associated With Increased Risk of Myeloid Disorders in Patients With Inflammatory Bowel Disease

Past exposure to immunosuppressive drugs called thiopurines has been found to increase the risk of myeloid disorders, such as acute myeloid leukemia and myelodysplastic syndrome, among patients with inflammatory bowel disease (IBD). The findings were reported by Lopez et al in Clinical...

leukemia

FDA Expands Approved Use of Ibrutinib for Chronic Lymphocytic Leukemia

The U.S. Food and Drug Administration (FDA) today expanded the approved use of ibrutinib (Imbruvica) to treat patients with chronic lymphocytic leukemia (CLL) who carry deletions of the short arm of chromosome 17, which are associated with poor responses to standard treatment for CLL. Ibrutinib...

hematologic malignancies
leukemia
lymphoma

FDA Approves Idelalisib for Three Types of Blood Cancers

The U.S. Food and Drug Administration (FDA) has approved idelalisib (Zydelig) for the treatment of patients with three types of blood cancers. Idelalisib is being granted traditional approval to treat patients with relapsed chronic lymphocytic leukemia (CLL). Used in combination with rituximab...

hematologic malignancies
leukemia

Researchers Identify Events Causing Bone Marrow Inflammation Leading to Blood Disorders

According to a new study, a cascade of molecular events in the bone marrow produces high levels of inflammation that disrupt normal blood formation and lead to potentially deadly disorders including leukemia. The discovery, published by the journal Cell Stem Cell, points the way to potential...

leukemia

FDA Grants Breakthrough Therapy Designation to Investigational Chimeric Antigen Receptor Therapy for Relapsed/Refractory ALL

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). The Breakthrough Therapy filing...

leukemia

FDA Grants Breakthrough Therapy Designation to Blinatumomab for Acute Lymphoblastic Leukemia

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to blinatumomab for adults with Philadelphia chromosome–negative relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow....

leukemia
issues in oncology

Novel Target Found for Chemotherapy-Resistant Leukemia Cells

Researchers at Children’s Hospital Los Angeles have discovered that by targeting a particular receptor, chemotherapy-resistant cancer cells can be killed in an acute form of childhood leukemia, offering the potential for a future treatment for patients who would otherwise experience relapse...

leukemia

FDA Approves Omacetaxine Mepesuccinate for Injection for Home Administration

The U.S. Food and Drug Administration (FDA) has approved omacetaxine mepesuccinate (Synribo) for injection, for subcutaneous use, to include home administration, and also approved a related Medication Guide and Instructions for Use. With this approval, physicians who treat adults with chronic- or...

leukemia

FDA Approves Mercaptopurine Oral Suspension for Acute Lymphoblastic Leukemia

On April 28, 2014, the U.S. Food and Drug Administration approved a 20 mg/mL oral suspension of mercaptopurine (Purixan) indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination regimen. Successive clinical trials have demonstrated that mercaptopurine ...

leukemia

FDA Grants Orphan Drug Designation to Alvocidib for the Treatment of Acute Myeloid Leukemia

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to alvocidib, a potent cyclin-dependent kinase small-molecule inhibitor, for the treatment of patients with acute myeloid leukemia (AML). The agent is being tested in patients with intermediate- or high-risk AML, who...

leukemia
issues in oncology

Researchers Uncover Link Between Down Syndrome and Leukemia

Although doctors have long known that people with Down syndrome have a heightened risk of developing acute lymphoblastic leukemia (ALL) during childhood, they haven’t been able to explain why. In a new study published online in Nature Genetics, Lane et al tracked the genetic chain of events...

leukemia

FDA Approves Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia

The U.S. Food and Drug Administration (FDA) today approved ofatumumab (Arzerra) injection in combination with chlorambucil (Leukeran) for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate. Trial...

leukemia

Volasertib Granted Orphan Drug Designation for Acute Myeloid Leukemia

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to volasertib for acute myeloid leukemia (AML). Volasertib is currently being evaluated in a phase III clinical trial for the treatment of patients aged 65 or older, with previously untreated AML, who are ineligible for ...

leukemia

Experimental Drug Shows Promise for Treatment-Resistant Leukemia

Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia. The study by Ma et al, published in Blood, found that ...

leukemia

CAR T-Cell Therapy Yields Promising Complete Response Rates in Patients With Relapsed/Refractory B-Cell ALL

In a recent study published in Science Translational Medicine, Davila et al found that 88% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) who were treated with genetically modified versions of their own immune cells achieved overall complete response. Most...

leukemia

Leukemia & Lymphoma Society Applauds FDA's Approval of Ibrutinib for CLL

In response to FDA's approval earlier this week of ibrutinib (Imbruvica) to treat patients with chronic lymphocytic leukemia (CLL) who had received at least one prior therapy, The Leukemia & Lymphoma Society (LLS) issued the following statement: "After the FDA designated ibrutinib as a...

leukemia
issues in oncology

Researchers Discover Preleukemic Stem Cell at Root of AML Relapse

Researchers have discovered a preleukemic stem cell that may be the first step in initiating disease and also the culprit that evades therapy and triggers relapse in patients with acute myeloid leukemia (AML). The research, published online in Nature, is a significant step forward in...

leukemia

Omacetaxine Mepesuccinate Receives Full FDA Approval for CML

The U.S. Food and Drug Administration (FDA) has granted full approval to omacetaxine mepesuccinate (Synribo) for injection. The full approval was based on the final analysis of two phase II trials that evaluated the efficacy and tolerability data of omacetaxine. The agent received an accelerated...

leukemia

FDA Approves Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia

The U.S. Food and Drug Administration (FDA) today expanded the approved use of ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one previous therapy. Ibrutinib, an oral Bruton’s tyrosine kinase inhibitor, was previously...

leukemia
lymphoma

FDA Approves Revised Prescribing Information for Ponatinib, Authorizes Resumption of Drug Sales and Distribution

The U.S. Food and Drug Administration (FDA) has approved revised prescribing information and a Risk Evaluation and Mitigation Strategy (REMS) for ponatinib (Iclusig) that allows immediate resumption of its marketing and commercial distribution. The prescribing information includes a revised...

leukemia

Ibrutinib/Rituximab Combination Leads to High Response Rate Among Patients With CLL

Nearly all of the patients with high-risk chronic lymphocytic leukemia (CLL) in a phase II clinical trial responded to treatment with the targeted therapy ibrutinib (Imbruvica) and the antibody rituximab (Rituxan), researchers reported at the 55th American Society of Hematology (ASH) Annual Meeting ...

hematologic malignancies
leukemia

Gemtuzumab Ozogamicin Reduces Minimal Residual Disease in Children With High-Risk Acute Myeloid Leukemia

Combining gemtuzumab ozogamicin (Mylotarg) with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high-risk acute myeloid leukemia (AML), according to a study led by St. Jude Children’s Research Hospital. The results appear in the...

leukemia

FDA Approves Obinutuzumab for Chronic Lymphocytic Leukemia

The U.S. Food and Drug Administration (FDA) today approved obinutuzumab (Gazyva) for use in combination with chlorambucil (Leukeran) to treat patients with previously untreated chronic lymphocytic leukemia (CLL). Obinutuzumab is the first drug with Breakthrough Therapy designation to receive FDA...

leukemia

Sale of Ponatinib Suspended Due to Risk of Life-Threatening Blood Clots

The U.S. Food and Drug Administration (FDA) has asked the manufacturer of the tyrosine kinase inhibitor ponatinib (Iclusig) to suspend marketing and sales of the drug because of the risk of life-threatening blood clots and severe narrowing of blood vessels. Ariad Pharmaceuticals has agreed to...

leukemia

FDA Investigating Ponatinib After Increased Reports of Serious Blood Clots in Arteries and Veins

The U.S. Food and Drug Administration (FDA) is investigating an increasing frequency of reports of serious and life-threatening blood clots and severe narrowing of blood vessels of patients taking the antileukemia drug ponatinib (Iclusig). Ponatinib is indicated for the treatment of patients with...

leukemia

FDA Grants Volasertib Breakthrough Therapy Designation in Acute Myeloid Leukemia

Boehringer Ingelheim Pharmaceuticals, Inc, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to volasertib, an investigational inhibitor of polo-like kinase (Plk), which being evaluated for the treatment of patients aged 65 or older with...

leukemia

FDA Grants Ofatumumab Breakthrough Therapy Designation for Previously Untreated CLL

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for ofatumumab (Arzerra) in combination with chlorambucil (Leukeran) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have not received prior treatment and are inappropriate for...

leukemia
issues in oncology

Researchers Uncover Genetic Cause of Childhood Acute Lymphoblastic Leukemia

For the first time, a genetic link specific to risk of childhood leukemia has been identified, according to a team of researchers from Memorial Sloan-Kettering Cancer Center, St. Jude Children’s Research Hospital, University of Washington, and other institutions. The discovery was reported...

leukemia

St. Jude's Study Yields New Strategy Against High-Risk Leukemia

St. Jude Children’s Research Hospital investigators have identified a protein that certain high-risk acute lymphoblastic leukemia (ALL) cells need to survive and have used that knowledge to fashion a more effective method of killing tumor cells. The findings appear in the August 29 edition of ...

leukemia

Preclinical Study Finds Tumor Suppressor May Actually Fuel Aggressive Acute Myeloid Leukemia

A study published this week in the Journal of Clinical Investigation suggests that blocking the RUNX1 protein normally credited with suppressing leukemia may be a promising therapeutic strategy for acute myeloid leukemia. Transcription Factor RUNX1 Researchers from Cincinnati Children's Hospital...

leukemia

Vaccine Stirs Immune Activity Against Advanced Chronic Lymphocytic Leukemia

Patients with advanced chronic lymphocytic leukemia (CLL) often receive allogeneic transplants that effectively “reboot” their own immune defenses, which then attack and potentially cure the hard-to-treat disease. However, there is a high rate of relapse in these patients, and the...

leukemia

Acute Myeloid Leukemia Induces Bone Marrow Failure by Inhibiting Production of Hematopoietic Stem Cells

Scientists studying acute myeloid leukemia (AML) have discovered that rather than displacing hematopoietic stem cells in the bone marrow as previously believed, the cancer is in fact inhibiting production of downstream hematopoietic cells, effectively putting them to sleep. The findings were...

leukemia
lymphoma

New Drug Application Submitted for Ibrutinib in the Treatment of Two B-cell Malignancies

Pharmacyclics, Inc, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational oral Bruton's tyrosine kinase inhibitor ibrutinib, for two relapsed/refractory B-cell malignancy indications: mantle cell lymphoma (MCL) and...

hematologic malignancies
leukemia

Technologies for Monitoring Minimal Residual Disease May Help Predict Outcomes for Patients with Leukemia

New evidence suggests that using advanced genetics technologies to monitor for remaining cancer cells after treatment may soon become an effective tool to inform treatment decisions and ultimately predict patient outcomes for patients with a particularly aggressive form of acute lymphocytic...

leukemia

African Americans with Chronic Lymphocytic Leukemia Do Not Live as Long as Caucasians, Despite Equal Care

A new analysis has found that among patients with chronic lymphocytic leukemia (CLL), African Americans more commonly present with advanced disease and tend to have shorter survival times than Caucasians despite receiving the same care. The results, published early online in Cancer, suggest that...

Advertisement

Advertisement



Advertisement